Log in or create an account for full access to this data.
Create a free account or log in to use this tool.
Create a free account or log in to explore DrugBank data.
Fludeoxyglucose (18F) is a radiopharmaceutical agent used for positron emission tomography (PET) imaging in oncology, cardiology, and neurology. It is administered by intravenous injection.
- Mechanism
- Curator reviewed
Fludeoxyglucose F 18 is a glucose analog that concentrates in cells that rely upon glucose as an energy source, or in cells whose dependence on glucose increases under pathophysiological conditions. Fludeoxyglucose F 18 is transported through the cell membrane by facilitative glucose transporter proteins and is phosphorylated within the cell to [18F] FDG-6- phosphate by the enzyme hexokinase. Once phosphorylated it cannot exit until it is dephosphorylated by glucose-6-phosphatase. Therefore, within a given tissue or pathophysiological process, the retention and clearance of Fludeoxyglucose F 18 reflect a balance involving glucose transporter, hexokinase and glucose-6- phosphatase activities. When allowance is made for the kinetic differences between glucose and Fludeoxyglucose F 18 transport and phosphorylation (expressed as the “lumped constant” ratio), Fludeoxyglucose F 18 is used to assess glucose metabolism. In comparison to background activity of the specific organ or tissue type, regions of decreased or absent uptake of Fludeoxyglucose F 18 reflect the decrease or absence of glucose metabolism. Regions of increased uptake of Fludeoxyglucose F 18 reflect greater than normal rates of glucose metabolism.
- Primary indication
- The uptake of 18F-FDG by tissues is a marker for the tissue uptake of glucose, which in turn is closely correlated with certain types of tissue metabolism.Curator reviewed · 4 structured indications
- Formula / weight
- C6H11FO5 · 181.15 g/mol (avg)
- First approval
- United States, 2005
- Also known as
- (18F)-FDG · 18-F FDG · 18F-FDG · 18F-Fluorodeoxyglucose · Fludeoxyglucose F 18
Resolves to
AOYNUTHNTBLRMT-MXWOLSILSA-NSMILES[H]C(=O)[C@H]([18F])[C@@H](O)[C@H](O)[C@H](O)COWhat you can answer from here — as of July 11, 2026
Which drugs share a target with Fludeoxyglucose (18F), and which of those have an active Phase 3 trial?